Cosmos Health Inc.

Equities

COSM

US2214133058

Pharmaceuticals

Delayed Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.71 USD +0.03% Intraday chart for Cosmos Health Inc. +14.33% -49.65%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cosmos Health Inc. Commences Development of Cloudscreen 2.0 the New Iteration of Its Next Generation AI Drug Repurposing Platform CI
Cosmos Health Inc. Receives Regulatory Approval to Sell Sky Premium Life Products in UAE Nutritional Supplements Market CI
Cosmos Health Acquires Rights to Patent for Drug Targeting Central Nervous System Cancers MT
Cosmos Health Files Patent Application for Obesity, Weight Management Product With European Patent Office MT
Tranche Update on Cosmos Health Inc.'s Equity Buyback Plan announced on January 24, 2023. CI
Cosmos Health Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Cosmos Health Insider Bought Shares Worth $158,806, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Softer Late Afternoon MT
Sector Update: Health Care Stocks Drop Wednesday Afternoon MT
Cosmos Health Says it has Agreed to Buy Cloudscreen in a Cash-and-Stock Deal. MT
Cosmos Health Inc. has entered into a purchase agreement to acquire Cloudscreen. CI
Cosmos Health to Continue to Pursue Active Ongoing Acquisitions CI
Sector Update: Health Care Stocks Slipping Late Afternoon MT
Sector Update: Health Care Stocks Retreating Wednesday Afternoon MT
Sector Update: Health Care MT
Cosmos Health Says Exploring Spinoff of R&D Division Into Publicly Listed Company; Shares Drop MT
Cosmos Health Inc. agreed to Spin-Off Research and development (R&D) division of Cosmos Health Inc. CI
Cosmos Health Inc. Announces Executive and Board Changes CI
Cosmos Health Forms Strategic Partnership with C.A.PAPAELLINAS Group MT
Cosmos Health Inc. Announces Strategic Collaboration with C.A.PAPAELLINAS Group CI
Cosmos Health Inc. Provides Earnings Guidance for the Year 2023 CI
Sector Update: Health Care Stocks Declining Late Afternoon MT
Sector Update: Health Care Stocks Advancing Tuesday Afternoon MT
Sector Update: Health Care MT
Cosmos Health Issues 2026 Outlook; Shares Jump MT
Chart Cosmos Health Inc.
More charts
Cosmos Health Inc. is a global healthcare company. The Company owns a portfolio of pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe and C-Sept. Through its subsidiary, Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It distributes a line of pharmaceuticals and Para pharmaceuticals, including branded generics and over the counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It is also engaged in the research and development (R&D) of patented nutraceuticals and specialized root extracts as well as in the R&D of complex generics and OTC products. It offers Cloudscreen, a multimodal platform specialized in drug repurposing, a process of uncovering new target proteins. It is also specialized in the storage and distribution of pharmaceutical and Para pharmaceutical goods.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.71 USD
Average target price
4 USD
Spread / Average Target
+463.38%
Consensus